Delia Goletti
Overview
Explore the profile of Delia Goletti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
277
Citations
9816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alonzi T, Petruccioli E, Aiello A, Repele F, Goletti D
Int J Infect Dis
. 2025 Mar;
:107880.
PMID: 40086617
Tuberculosis (TB) remains the leading cause of death worldwide from a single infectious disease. An estimated quarter of the world's population, about 2 billion people, has an immune response to...
2.
Zumla A, Sahu S, Yeboah-Manu D, Goletti D, Nyasulu P, Mfinanga S, et al.
Lancet
. 2025 Mar;
PMID: 40023179
No abstract available.
3.
Di Bari V, Cerva C, Libertone R, Carli S, Musso M, Goletti D, et al.
Infect Dis Rep
. 2025 Feb;
17(1).
PMID: 39997463
Background/objectives: Tuberculosis (TB) remains a major global health issue, further complicated by the COVID-19 pandemic. This study assesses the clinical outcomes of TB-COVID-19-coinfected patients compared to those with TB disease...
4.
Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori G, Goletti D
Front Immunol
. 2025 Feb;
16:1494283.
PMID: 39963138
Tuberculosis (TB) is the leading cause of death in the world from an infectious disease. Its etiologic agent, the (Mtb), is a slow-growing bacterium that has coexisted in humans for...
5.
Farroni C, Altera A, Salmi A, Vanini V, Cuzzi G, Arlehamn C, et al.
Front Immunol
. 2025 Jan;
15:1484143.
PMID: 39872515
Background: Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis, with tuberculosis infection (TBI), have a high probability of progressing to tuberculosis disease (TB). We aim to characterize the...
6.
Licata M, Mencarini P, Mastrobattista A, Carli S, Cerva C, Mosti S, et al.
Pathogens
. 2025 Jan;
13(12.
PMID: 39770324
Diagnosing non-tuberculous mycobacterial pulmonary disease (NTM-PD) in patients unable to produce sputum spontaneously requires invasive procedures to obtain valid respiratory specimens. In this retrospective study, we evaluated the results of...
7.
Khelghati F, Rahmanian M, Eghbal E, Seghatoleslami Z, Goudarzi M, Keramatinia A, et al.
New Microbes New Infect
. 2024 Dec;
62:101533.
PMID: 39639969
Introduction: Tuberculosis (TB) risk associated with tumor necrosis factor-alpha (TNF-α) antagonist therapy in patients with autoimmune diseases is a significant concern. This study aims to evaluate the risk of TB...
8.
Goletti D, Meintjes G, Andrade B, Zumla A, Lee S
Int J Infect Dis
. 2024 Dec;
150:107325.
PMID: 39631498
No abstract available.
9.
Najafi-Fard S, Farroni C, Petrone L, Altera A, Salmi A, Vanini V, et al.
Front Immunol
. 2024 Nov;
15:1411827.
PMID: 39530101
Objective: Cysteamine, a drug approved to treat cystinosis, has been proposed as a host-directed therapy for (Mtb) and SARS-CoV-2. The impact of cysteamine on the immune responses has not been...
10.
Prosperini L, Arrambide G, Celius E, Goletti D, Killestein J, Kos D, et al.
Lancet Reg Health Eur
. 2024 Oct;
44:100979.
PMID: 39429966
During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare providers have faced unique challenges related to the interaction between SARS-CoV-2, underlying neurological disease and the use of...